Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors

Author： Steeghs Neeltje   Gelderblom Hans   Wessels Judith   Eskens Ferry   Bont Natasja   Nortier Johan   Guchelaar Henk-Jan  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.29, Iss.1, 2011-02, pp. : 137-143

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy

By Shin Sang  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1501-1510

Springer Publishing Company

Access to resources Recommend Favorite

Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect

By  

Current Medicinal Chemistry, Vol. 23, Iss. 10, 2016-03 ,pp. : 1000-1040

Bentham Science Publishers

Access to resources Recommend Favorite

Exploring QSARs of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Tyrosine Kinase Inhibitors by MLR, PLS and PC-ANN

By  

Current Pharmaceutical Design, Vol. 19, Iss. 12, 2013-01 ,pp. : 2237-2244

Bentham Science Publishers

Access to resources Recommend Favorite

VEGF-Induced Growth Cone Enhancement Is Diminished by Inhibiting Tyrosine-Residue 1214 of VEGFR-2

By  

Cells Tissues Organs, Vol. 196, Iss. 3, 2012-03 ,pp. : 195-205

Karger

Access to resources Recommend Favorite

Molecular Design and Clinical Development of VEGFR Kinase Inhibitors

By  

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 14, 2007-07 ,pp. : 1379-1393

Bentham Science Publishers

Access to resources Recommend Favorite